Balyasny Asset Management
SIOX

Balyasny Asset Management’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Balyasny Asset Management’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-20,811
Closed -$221K – 2249
2018
Q1 		$221K Buy
20,811
+17,461
+521% +$280K ﹤0.01% 1725
2017
Q4 		$141K Sell
3,350
-4,275
-56% -$192K ﹤0.01% 1950
2017
Q3 		$420K Buy
+7,625
New +$1.29M ﹤0.01% 1412

Other funds holding SIOX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Balyasny Asset Management's SIOX Position: Q2 2018 in Review

Balyasny Asset Management sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2018, closing a stake of 20,811 shares — an estimated $221K sold.

Balyasny Asset Management first reported a position in SIOX in Q3 2017 and held it in 3 quarters. The position peaked at $420K in Q3 2017. 71 funds tracked by Wall St. Rank hold SIOX as of Q2 2018.

  • Balyasny Asset Management reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 20,811 Sio Gene Therapies Inc. Common Stock shares in Q2 2018, an estimated $221K.
  • Balyasny Asset Management first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2017 and held it in 3 quarters.
  • Balyasny Asset Management's Sio Gene Therapies Inc. Common Stock position peaked at $420K in Q3 2017.
  • 71 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.